What is the current price of ALNEV.PA stock and its recent volume?

ALNEV.PA stock trades at **€0.0008** pre-market on 24 Mar 2026 with volume **35,245,238**, well above its average of **16,097,961**, indicating elevated liquidity and volatility.

What drives ALNEV.PA stock performance?

ALNEV.PA stock performance is driven mainly by clinical trial progress, regulatory news, and low-liquidity swings; company pipeline updates for IFNa Kinoid are primary catalysts.

What is Meyka AI's forecast for ALNEV.PA stock?

Meyka AI's forecast model projects a monthly target of **€0.04** for ALNEV.PA stock versus the current **€0.0008**, implying a theoretical upside near **4,900%**; forecasts are model-based and not guarantees.

What grade does Meyka AI assign to ALNEV.PA stock?

Meyka AI rates ALNEV.PA with a score of **61.99/100**, Grade **B** with a HOLD suggestion, based on benchmarks, sector metrics, financial growth and analyst signals.

EU Stocks

Pre-market most active: ALNEV.PA Neovacs Euronext €0.0008 24 Mar 2026: monitor

ByDanny Kontos March 24, 2026

ALNEV.PA stock is trading pre-market at €0.0008 on 24 Mar 2026 after a one-day decline of -11.11%. We highlight heavy activity on Euronext with 35,245,238 shares changing hands versus an average volume of 16,097,961, a relative volume of 2.19. This activity puts Neovacs S.A. (ALNEV.PA) among the most active pre-market names in Europe and raises liquidity and execution risk for small orders. Investors should weigh the biotech pipeline and balance-sheet metrics against extreme price volatility in the pre-market session.